Latest news with #TriLink
Business Wire
5 days ago
- Business
- Business Wire
TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology
SAN DIEGO--(BUSINESS WIRE)-- TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink's CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to patients worldwide. "Strengthening global health against infectious diseases requires strong industry partnerships," said Becky Buzzeo, Chief Commercial Officer at Maravai. TriLink's CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when compared to legacy capping methods. Under this agreement, TriLink will supply its patented CleanCap technology for use in Quantoom's (sa)mRNA production platform, allowing customers to benefit from the industry's leading capping technology to develop their unique (sa)mRNA drugs using the Ntensify platform through clinical development phases. "Strengthening global health against infectious diseases requires strong industry partnerships," said Becky Buzzeo, Chief Commercial Officer at Maravai. "We're excited for the Quantoom production platform to incorporate TriLink's CleanCap reagents, a proven mRNA capping technology to deliver essential therapeutics and vaccines to nations with limited resources." Since its debut in 2017, TriLink's CleanCap capping technology has transformed the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. 'We are committed to making the RNA technology more accessible and scalable, and this partnership with TriLink is a key step toward that goal," said José Castillo, CEO of Quantoom Biosciences. "By integrating CleanCap analogs into our platform, we can further empower researchers and manufacturers to develop life-saving vaccines and therapeutics for communities in need." About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans. For more information about TriLink, visit About Maravai LifeSciences Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit About Quantoom Biosciences Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force TM toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode TM for sequence design and optimization, Ntensify ® for RNA production and Ncapsulate ® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
Yahoo
20-05-2025
- Business
- Yahoo
TriLink BioTechnologies® debuts its first mRNA synthesis kit with CleanCap® capping technology; Celebrates launch with kit donations to top academic institutions
New all-in-one IVT kit can deliver up to 2X more mRNA and up to 85% lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced dsRNA, and enhanced performance SAN DIEGO, May 20, 2025--(BUSINESS WIRE)--TriLink BioTechnologies® (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI), is fueling the future of mRNA research — starting with a significant donation to top academic labs across the U.S. and Europe. The donation commemorates the launch of TriLink's first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative products in one box at a competitive price. Seven academic institutions will receive ten kits each that can yield up to a combined 250mg of capped mRNAs, enabling and encouraging further discovery and development in the field of mRNA-based medicine. Labs in academic institutions, such as those listed below, have gratefully accepted the kits donated by TriLink to drive progress in RNA therapeutics and build a strong future for the field. The Center for RNA Therapeutics at Houston Methodist Research Institute (HMRI) The Center of RNA Technologies and Therapeutics at UC San Diego The University Medical Center Utrecht The University of Oxford Yale School of Medicine The new in vitro transcription (IVT) kit will simplify mRNA synthesis and elevate IVT by leveraging TriLink's high-performing products where users can expect up to 2X more mRNA yield and up to 85% lower dsRNA compared to other kits on the market. The IVT kit components include: CleanCap® AG (3′ OMe) for co-transcriptional capping CleanScribe™ RNA Polymerase for dsRNA reduction Nucleotides including N1-methylpseuouridine for enhanced mRNA performance, and CleanScript® IVT for increased yield. "This launch brings together a powerful suite of novel IVT components that reflect TriLink's years of experience and innovation in mRNA synthesis," shared Justin Barbosa, Vice President & General Manager of TriLink Discovery. "By offering all these components in a single kit, we're simplifying researcher workflow and accelerating discovery. The addition of CleanScript IVT optimization also ensures our customers can generate more high-quality mRNA per reaction — maximizing both efficiency and performance." The kit comes ready to use and is the only commercially available IVT kit featuring CleanCap AG (3′ OMe), which is a modified version of the original CleanCap AG with over 95% capping efficiency to improve protein expression. CleanCap co-transcriptional capping provides advantages over legacy capping methods of ARCA or enzymatic by streamlining mRNA manufacturing with fewer steps and handling, thereby saving researchers time and resources. "This is an important product launch, where we are bringing several technology and process improvements to an integrated IVT kit," said Trey Martin, CEO of Maravai. "Today we are also making a statement about our commitment to the future of mRNA science. By donating the first new kits to top academic institutions across the U.S. and Europe, we are investing in the next generation of mRNA innovators and empowering groundbreaking research that could lead to the therapies of tomorrow. We are honored to help our field continue to evolve and improve through new innovations and process improvements." With more than 25 years of experience in nucleic acid product development and manufacturing, TriLink is a recognized leader in advancing mRNA and oligo-based therapeutic innovation. Its CleanCap AG (3′ OMe) cap analog is used in commercially approved vaccines, of which billion of doses have been administered worldwide with a tremendous safety profile. TriLink's reagents and services are available for research use only (RUO) and for GMP manufacturing, supporting applications from discovery to commercialization in the genomic space. If you are interested in research & development collaboration, visit To learn more about TriLink's products and services, visit About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans. For more information about TriLink, visit About Maravai LifeSciences Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit View source version on Contacts Investor Contact:Deb HartMaravai LifeSciences858-988-5917ir@ Media Contact:Liz Robinson of CG LifeTriLink BioTechnologies312-997-2436lrobinson@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
14-05-2025
- Business
- Business Wire
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines
SAN DIEGO--(BUSINESS WIRE)--Today, TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, and the International Vaccine Institute (IVI), a non-profit international organization devoted to and the discovery, development and delivery of vaccines for global health signed a Memorandum of Understanding to collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies. "This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries (LMICs),' said Maravai and TriLink's Chief Commercial Officer, Becky Buzzeo. According to the terms of the MOU, TriLink and IVI will enter discussions on collaborative models to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives. "This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries (LMICs),' said Maravai and TriLink's Chief Commercial Officer, Becky Buzzeo. 'By combining our expertise in nucleic acids with the International Vaccine Institute's global reach and commitment to public health, we are poised to profoundly impact global health equity. Together, we can accelerate the development and distribution of innovative mRNA vaccines, ensuring that more people, regardless of their geographic location, have access to the critical healthcare they need." Since its launch in 2017, TriLink's CleanCap® capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In 2024, TriLink expanded its products and services specifically for customers working in mRNA therapeutics, launching IVT enzymes, including CleanScribe™ RNA polymerase, which has been shown to reduce dsRNA, and opened its commercially ready GMP manufacturing facility in San Diego, California. IVI, based in Seoul, Korea, is an autonomous international organization established in 1997 as an initiative of the United Nations Development Program. It is dedicated exclusively to vaccines for global health, with a portfolio spanning all stages of pre-clinical and clinical development. Its work focuses on infectious diseases of global health importance, particularly those that disproportionately affect LMICs, including cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, and COVID-19. 'IVI is pleased to partner with TriLink BioTechnologies, a leading provider of life science reagents and services, including its proprietary capping technology that enhances mRNA stability and translation efficiency,' said Dr. Jerome Kim, Director General of IVI. 'This collaboration will empower the two organizations and our partners to accelerate the development and global delivery of advanced mRNA vaccines, especially to people in LMICs.' About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders to enabling future pandemic response plans. For more information, visit About Maravai LifeSciences Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit About the International Vaccine Institute (IVI) The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health. IVI's current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world's first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that also achieved WHO prequalification in early 2024. IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, an Africa Regional Office in Rwanda, a Country Office in Austria, and a Country and Project Office in Kenya. IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts Collaborating Centers in Ghana, Ethiopia, and Madagascar. 42 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, Austria, and Thailand provide state funding. For more information, please visit
Associated Press
04-02-2025
- Business
- Associated Press
TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap® mRNA capping technologies to those developing critical mRNA-based therapeutics and vaccines. According to the terms of the agreement, TriLink will supply its patented CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Aldevron's mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology produces optimal 5'Cap structures with over 95% efficiency, creating a co-transcriptional capping solution that improves mRNA yield and process time when compared to legacy capping methods. 'CleanCap technology is accelerating programs through drug development milestones and has been the capping technology of choice for mRNA constructs in 350+ preclinical and clinical programs,' shared Becky Buzzeo, Chief Commercial Officer, Maravai. 'We're excited to offer our innovative capping solutions to Aldevron and its manufacturing customers.' Since its launch in 2017, TriLink's CleanCap® capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap® analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods. Aldevron, based in Fargo, ND, is a leader in advancing biological science. Their custom development and manufacturing services provide scientists with essential components to accelerate research and breakthrough discoveries. About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders to enabling future pandemic response plans. For more information, visit About Maravai LifeSciences Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit About Aldevron Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, enzymes, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in Fargo, North Dakota, and as a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit Liz Robinson of CG Life TriLink BioTechnologies +1 312-997-2436 [email protected] Shafer Senior Director of Communications Aldevron O: 701-551-8704 [email protected] contact: Deb Hart Maravai LifeSciences + 1 858-988-5917 SOURCE: TriLink BioTechnologies Copyright Business Wire 2025. PUB: 02/04/2025 04:01 PM/DISC: 02/04/2025 04:02 PM
Yahoo
28-01-2025
- Business
- Yahoo
Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies
Molecular Assemblies proprietary Fully Enzymatic SynthesisTM technology to enhance mRNA and oligonucleotide manufacturing capabilities within the TriLink BioTechnologies business SAN DIEGO, January 28, 2025--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today its acquisition of intellectual property and relevant assets from Molecular Assemblies (MAI). The acquisition will expand Maravai and TriLink BioTechnologies' ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies. "Molecular Assemblies is the original leader in enzymatic oligo synthesis, with strong foundational IP. Their team has made great strides in designing and developing an enzymatic DNA synthesis platform with exciting technical advantages over traditional chemical synthesis," said Trey Martin, CEO of Maravai LifeSciences. "We plan to further evolve and enhance Molecular Assemblies' workflows to push the limits of oligo length and purity, and to lower costs by vertically integrating NTPs and enzymes from our TriLink and Alphazyme businesses." Justin Barbosa, GM and Vice President of TriLink Discovery, added "By integrating Molecular Assemblies technology into TriLink's capabilities, we can further incorporate DNA template manufacturing in our mRNA business. We also plan to expand our custom oligo offerings to support gene assembly, antibody screening, and CRISPR HDR donor workflows." Bill Efcavitch, Co-Founder of Molecular Assemblies, said, "We are pleased our customers will continue to be supported by TriLink, a leader in nucleic acid manufacturing with an excellent reputation for high quality and scientific expertise. TriLink is well positioned to advance and expand our technology as they work with innovators who are developing the next generation of nucleic acid-based vaccines and therapeutics." About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics and cell and gene therapies companies. About Molecular Assemblies Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company's patented Fully Enzymatic Synthesis (or FES™), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. FES technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of nanomachines and bio-based electronics. Molecular Assemblies is headquartered in San Diego. Forward-looking Statements This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to plans to further develop workflows to enhance oligo length and purity, plans to lower costs by vertically integrating NTPs and enzymes, and plans to expand product and service offerings, constitute forward-looking statements identified by words like "plan," "expect," "estimate," "may," "soon," "nears," "slated," "anticipate," or "could" and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, operational risks and competition. These and other risks and uncertainties are described in greater detail in the "Risk Factors" section of our most recent Annual Report on Form 10-K, as well as other reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law. View source version on Contacts Media Contact:Liz RobinsonCG Lifetrilink@ Investor Contact:Deb HartMaravai LifeSciences+ 1 858-988-5917ir@
